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Introduction
Ovarian sex cord-stromal tumors are a heterogeneous group 
of ovarian tumors that comprise approximately 5% to 8% of 
all ovarian malignancies [1]. Sertoli-Leydig cell tumors (SLCTs), 
also known as androblastomas, are a subset of ovarian sex 
cord-stromal tumors that constitute less than 0.2% of all 
ovarian tumors [2,3]. SLCTs are the most frequently observed 
low-grade malignancies, although poorly differentiated tu-
mors may behave more aggressively [4].
The tumors typically produce androgens, and clinical vir-
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ilization is noted in 70% to 85% of patients [5-8]. Signs of 
virilization include oligomenorrhea followed by amenorrhea, 
breast atrophy, acne, hirsutism, clitoromegaly, deepening 
voice, and receding hairline. Though frequently characterized 
by the androgen production, only 30% of patients display 
virilization or defeminization on presentation [2]. In particular, 
classic endocrine symptoms are rarely observed in retiform 
type SLCTs or those with heterologous elements [9]. Instead, 
these tumors are highly variable in their proportions of Sertoli 
cells, Leydig cells, and/or fibroblastic cells, and patients most 
often present with abdominal pain or distention.
Investigation of a large series of SLCT cases in a uniform 
manner is challenging for a single institute because of the 
paucity of cases [10]. In addition, varied pathology and tumor 
differentiation states make proper diagnosis and development 
of optimal treatment difficult [11-14]. An extended case series 
could provide valuable diagnostic and prognostic information, 
leading to precise therapeutic strategies.
This study aimed to evaluate the clinical and pathologic 
characteristics of patients who were diagnosed with ovarian 
SLCTs in a single institution. Patient outcomes and prognoses 
were investigated.
Table 1. Patient characteristics (n=11)
Case Age(yr) Chief complaint
Initial impression 
(tool) Operation
Specimen 
size (APD× 
transverse 
×height)
Stage Grade
1 30 Abdominal pain Mucinous adenocarcinoma
(APCT)
TAH, BSO, BPLD, 
omentectomy
20×20×15 Ic Intermediate differenti-
ated
2 50 Abdominal mass Adenocarcinoma from 
ovary (MRI)
TAH, BSO, partial 
omentectomy, PALS
Ic Poorly differentiated 
(Sertoli-form 
endometrioid carcinoma)
3 22 Dysmenorrhea Fibrosarcoma or granulosa 
cell tumor (MRI)
RSO 8×6×4 Ia Intermediate differenti-
ated
4 39 s/p breast cancer Fibroma (GY 
ultrasonography)
TLH, BSO, BPLD 4×2×2 Ic Poorly differentiated
5 70 Abdominal mass Varian malignat tumor 
(MRI)
TAH, BSO 19×14×9 Ic Unclassified
6 51 Abdominal disten-
sion
Adenocarcinoma 
from Lt adnexa with 
carcinomatosis (MRI)
TAH, BSO, BPLD, 
PALS, omentectomy, 
appendectomy
17×11×9 IIb Poorly differentiated 
(Sertoli-form 
endometrioid carcinoma)
7 16 Abnormal uterine 
bleeding
Germ cell tumor (MRI) RSO, BPLD, omentectomy 9×7×3 Ia Poorly differentiated 
8 20 Abdominal disten-
sion
Malignant epithelial tumor 
(borderline to malig) 
(APCT)
RSO, BPLD, omentectomy, 
appendectomy
Ia Poorly differentiated
9 17 Amenorrhea Malignant epithelial tumor 
(APCT)
LSO 7×4×2 Ic Poorly differentiated
10 45 Primary amenorrhea 
(MRKH syndrome)
Laparoscopic BSO, BPLD IIb Well differentiated
11 31 Oligomenorrhea Fibroma (GY 
ultrasonography)
Laparoscopic LSO, 
omentectomy Lt LPLD, 
PALS
5×4×2 Ic Intermediate differenti-
ated
APD, anterior-posterior diameter; APCT, abdomen-pelvis computer tomography; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-
oophorectomy; BPLD, bilateral pelvic lymph node dissection; PALS, paraaortic lymph node sampling; MRI, magnetic resonance imanging; RSO, 
right salpingo-oophorectomy; GY, gynecology; TLH, total laparoscopic hystectomy; LSO, left salpingo-oophorectomy; MRKH syndrome, Meyer-
Rokitansky-Kustner-Hauser syndrome; LPLD, left pelvic lymph node dissection.
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Materials and methods
The present study was approved by institutional review board 
of Yonsei University. The medical records of 11 patients who 
were pathologically diagnosed with SLCTs of the ovary were 
reviewed. All patients were treated in a single institute from 
1995 to 2014. The collected data included age, past medical 
history, initial symptoms and signs, initial imaging findings, 
type of surgery, incision type, stage, histological type, che-
motherapy regimens, and prognosis. Patients were staged 
according to the International Federation of Gynecology and 
Obstetrics (FIGO) classification of ovarian tumors [15]. Experi-
enced pathologists who specialized in gynecologic oncology 
examined all specimens.
Based on a pathological review, the cases were divided into 
1 of the 4 SLCT categories. Grade 1 tumors were well dif-
ferentiated and contained a significant component of Leydig 
cells as well as Sertoli cells. Grade 2 tumors exhibited interme-
diate differentiation, and tumors were composed of immature 
Sertoli cells are typically arranged in a diffuse pattern. Grade 3 
tumors were poorly differentiated. Those tumors were largely 
composed of tissue resembling an undifferentiated gonad and 
may resemble sarcomas. Other tumors had an unclassified 
heterologous element, and they were tumors of intermediate 
or poor differentiation that contained cell types foreign to the 
developing gonad [4].
For all patients, surgery was the initial treatment. For 
women who opted to spare fertility, a unilateral salpingo-oo-
phorectomy was performed. Total hysterectomy and bilateral 
salpingo-oophorectomy with omentectomy, appendectomy, 
pelvic lymph node dissection, and para-aortic lymph node 
sampling were performed as a staging operation in other 
cases. Patients were administered postoperative adjuvant che-
motherapy after surgery and were followed-up periodically 
using clinical, serologic, and radiological evaluations.
Results
The median age of the patients was 31 years, ranging from 
16 to 70 years. The initial chief complaints can be divided into 
two main groups: menstrual disorders and nonspecific symp-
toms caused by ovarian masses. The largest group of patients 
(54%, 6/11) presented with nonspecific symptoms, including 
abdominal pain, palpable mass, and abdominal distension. 
Two patients experienced amenorrhea. There was a single 
case of oligomenorrhea and dysfunctional uterine bleeding 
each. Initial imaging findings suggested a malignant epithelial 
ovarian tumor in 6 cases, a germ cell tumor in 2 cases, and 
fibroma in 2 cases (Table 1).
Grade 3 tumors were found in 6 patients (54.5%, 6/11), 
grade 2 tumors were found in 3 patients (27.3%, 3/11), and 
a grade 1 tumor was found in 1 patient (9.1%, 1/11). One 
patient had a tumor of unclassified grade (9.1%, 1/11), which 
was a pure stromal tumor composed of cells that resemble 
Leydig cells (Fig. 1). Eight patients were administered adjuvant 
chemotherapy after surgery, consisting of a bleomycin, eto-
poside, and cisplatin (BEP) regimen in 6 cases, a modified BEP 
regimen in 1 case, and combined paclitaxel and cisplatin in 
1 case. Three patients who had IA/grade 2, IA/grade 3, or IC 
disease were not administered postoperative chemotherapy. 
Two of the 11 patients suffered disease recurrence and died 
of the disease 10 years after the operation. Of note, the tu-
mors from these 2 patients were pathologically re-diagnosed 
as Sertoli-form endometrioid carcinoma (SEC). The other 9 
patients remain alive without evidence of recurrence at the 
time of reporting (Table 2).
Surgeries were performed as initial management for all 
11 patients, and the 4 patients without children underwent 
fertility-sparing surgery. Seven patients had more extensive 
full staging surgery that included total abdominal or laparo-
scopic hysterectomy with bilateral salpingo-oophorectomy. 
Additionally, 8 of 11 patients underwent pelvic lymph node 
Fig. 1. Pathology of Sertoli-Leydig cell tumor. There are solid tumors 
with round uniform cells vacuolated or pink granular cytoplasma and 
pigment (H&E, ×200).
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dissections. Three of the 11 patients underwent laparoscopic 
surgery, and 8 patients underwent laparotomies (Table 3). 
Tumors ranged from 2 to 20 cm in size and weighed 90 to 
1,190 g. Most tumors had a smooth intact surface and were 
confined to the ovary (81.8%, 9/11), as seen in other series 
[16]. Three of the 11 patients (27.3%) had a tumor confined 
to one ovary (stage IA), 6 patients (54.5%) had tumors that 
ruptured during surgery (stage IC), and the other 2 patients 
(18.2%) presented with a tumor that had spread beyond the 
ovaries (stage IIb). No patients had bilateral disease (stage IB) 
(Table 1).
Discussion
SLCTs are a very rare type of sex cord-stromal tumor of ovary, 
accounting for less than 0.5% of all ovarian tumors [17], and 
little is known about them. SLCTs comprise diverse pathologic 
characteristics that can help pathologists and gynecologists 
make correct diagnoses, including primary and metastatic 
ovarian cancer [18]. In this study, patient age ranged from 
17 to 70 years, and the average age was 31 years. SLCTs are 
more often encountered in young women. If a young woman 
has a pelvic mass and virilization, SLCT should be included in 
the differential diagnosis. Most of these tumors are unilateral 
and are diagnosed as stage I. Conservative surgery could be 
sufficient in young patients, and especially for those women 
who still wish to have children, a fertility sparing unilateral 
salpingo-oophorectomy and close observation could be ben-
eficial. Hysterectomy and bilateral salpingo-oophorectomy, or 
full staging, with adjuvant chemotherapy would be the optimal 
treatment for women who do not need fertility preservation.
 The stage and degree of tumor differentiation are the most 
important prognostic factors for these patients. For patients 
with poorly differentiated tumors, more aggressive man-
agement is needed because there is a high probability that 
these lesions will be malignant. An individualized treatment 
approach is necessary for patients with intermediately dif-
ferentiated tumors. If patients have poor prognostic factors, 
adjuvant chemotherapy should be considered. 
Owing to the rarity of this disease, there is still no consensus 
on the optimal management of SLCT or the most appropriate 
alternative therapy to treat stage I disease, which could in-
volve chemotherapy, radiotherapy, and/or hormonal therapy. 
The BEP regimen is comparatively safe because it does not 
Table 3. Rate of surgery type, whether fertility sparing surgery 
and lymph node dissection
Type/operation method  Number (%)
Type
Laparotomy 8 (73)
Laparoscopy 3 (27)
Fertility sparing surgery
Yes 6 (55)
No 5 (45)
Lymph node dissection
Yes 8 (73)
No 3 (27)
Table 2. Treatment and prognosis of Sertoli-cell tumor
Case Adjuvant chemotherapy Chemotherapy regimen Cycle Follow-up
1 Yes Bleomycin, etoposide, neoplatin 3 Alive
2 Yes Paclitaxel, carboplatin 6 Death
3 Observation - - Alive
4 Yes Bleomycin, etoposide, cisplatin 4 Lung metastasis of 
breast cancer
5 Observation - - Alive
6 Yes Etoposide, cisplatin 4 Death
7 Conservative management - - Alive
8 Yes Bleomycin, etoposide, cisplatin 4 Alive
9 Yes Bleomycin, etoposide, cisplatin 6 Alive
10 Yes Bleomycin, etoposide, cisplatin 1 Alive
11 Yes Bleomycin, etoposide, cisplatin 4 Alive 
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affect patient fertility status [19]. However, there has been no 
large-scale multicenter study to establish which chemotherapy 
regimen would be most effective, what the appropriate treat-
ment would be for recurrence, or what the key prognostic 
factors are. A study by Brown et al. [20] in 2005 suggested an 
alternative regimen utilizing taxanes with or without a plati-
num agent, for the treatment of SLCTs. 
To the best our knowledge, early stage SLCTs, such as 
well-differentiated stage IA tumors, are usually considered 
benign in South Korea, based on previous studies analyzing 
clinicopathological characteristics of the disease [21,22]. Ac-
cording to the Korean standard disease classification, which 
is based on the World Health Organization classification, 
well-differentiated Sertoli-Leydig cell tumor is classified using 
disease code M8631/0. Code number 0 in the Korean clas-
sification specifies benign disease. Well-differentiated SLCT 
is considered benign, for which chemotherapy should not be 
administered. Among our cases, 1 case of well-differentiated 
SLCT was treated with chemotherapy due to accompanying 
stage IIB Meyer-Rokitansky-Kustner-Hauser syndrome. In our 
case series, 3 of 11 patients did not receive chemotherapy. 
Two of those patients were diagnosed with staged Ia disease, 
and the other was diagnosed with stage Ic disease. To date, 
all patients who were treated with surgery alone are alive. 
Chemotherapy use can be determined flexibly based on stage 
and patient performance status in SLCT treatment.
In our study, 8 of the 11 patients underwent platinum-
based chemotherapy, and all except 2 are still alive at the time 
of reporting, including the 3 patients who did not undergo 
chemotherapy. Our findings suggest that, regardless of his-
tologic grade or FIGO stage of ovarian SLCTs, the prognosis 
of these patients is generally excellent, even if no adjuvant 
chemotherapy is administered. Indeed, the 2 patients who 
succumbed to their disease were ultimately found not to have 
a SLCT. Sigismondi et al. [23] recommended in 2012 that 
platinum-based adjuvant chemotherapy be given to any pa-
tient with grade 2 to 3 disease, as prognoses for patients with 
disease stage >I and relapsed patients were poor.
First described by Young et al. in 1982 [24], SEC is a rare 
entity that is histologically similar to SLCT, which can result in 
even experienced pathologists misdiagnosing these tumors 
(Fig. 2). There are 2 different histologic points present in SEC 
contrary to SLCTs: (1) the parts with the typical pattern of en-
dometrioid carcinoma and (2) the part of mucin at the apical 
borders of the tumor cells [25]. Even though they are similar 
in histology, there are important clinical differences between 
these two entities. SECs almost exclusively arise in postmeno-
pausal women, with an average age of diagnosis between 
60 and 70 years. In contrast, patients with SLCT tend to be 
younger, with an average age of diagnosis of 25 years, and 
may have hormonal signs, such as virilization [26]. Corre-
spondingly, the 2 patients who were finally diagnosed with 
SEC in this study were relatively old. 
The majority of SECs described in past reports were initially 
misdiagnosed as SLCT [24]. Virilizing symptoms, though un-
common in endometrioid carcinoma, may be encountered in 
the Sertoli-form variant, making the diagnosis more difficult 
[25]. Taken together, this suggests that extensive sampling 
of the specimen and close investigation is necessary before 
making a diagnosis of SLCT, especially in postmenopausal 
patients. Recognition of this tumor is important, as it is a well-
differentiated, low-grade malignancy that is associated with a 
good prognosis when confined to the ovary [25,27]. On the 
other hand, SEC areas are usually classified as grade 3 based 
on the current FIGO grading system [27]. The two patients 
who expired in our study had poor prognoses.
There have also been a few case reports of successful lapa-
roscopic removal of these tumors [28]. Laparoscopic surgery 
was performed in 3 patients in this study, and the patients all 
had equivalent outcomes to patients who underwent lapa-
rotomies. Laparoscopic surgery would be preferable in most 
cases, as it is minimally invasive, leaves less scaring, and is as-
sociated with a quicker recovery.
In the present study, we investigated clinical and pathologic 
Fig. 2. Sertoliform endometrioid carcinoma. The pathologic feature is 
similar to the Sertoli-Leydig cell tumors (H&E, ×200).
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characteristics of patients who were diagnosed as ovarian 
SLCTs in a single institution. Additionally, we evaluated patient 
outcomes and prognoses. Initial chief complaints related with 
virilization were present in only 4 cases, which was consistent 
with a previous report [2]. Patient prognoses were favorable 
in our study, even for patients did not receive adjuvant che-
motherapy, and laparoscopy was a feasible approach to treat 
disease. A multi-centered study with more patients will be 
required to better understand SLCTs.
In conclusion, conservative surgery in a young patient who 
still wishes to have children is sufficient. Hysterectomy and bi-
lateral salpingo-oophorectomy, or full staging, with adjuvant 
chemotherapy is the best treatment for patients who do not 
wish to spare fertility. However, if the patient, pathologically, 
has well-differentiated cell stage Ia disease, then chemothera-
py is not necessary, as that is considered as benign disease.
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